Cargando…

A Low Level of Darunavir Resistance–Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort

BACKGROUND: Ritonavir-boosted darunavir (DRV/r) is a protease inhibitor (PI) indicated for the treatment of naïve and pretreated HIV-infected patients since 2007. Our study aims to describe DRV/r-treated patients experiencing virological failure (VF) documented with HIV resistance testing. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaussade, Hélène, Tumiotto, Camille, Le Marec, Fabien, Leleux, Olivier, Lefèvre, Lucile, Lazaro, Estibaliz, Lafon, Marie-Edith, Nyamankolly, Elsa, Duffau, Pierre, Neau, Didier, Bellecave, Pantxika, Bonnet, Fabrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772944/ https://www.ncbi.nlm.nih.gov/pubmed/33409332 http://dx.doi.org/10.1093/ofid/ofaa567

Ejemplares similares

Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort’s QuAliV ancillary study
por: Barger, Diana, et al.
Publicado: (2020)

Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort
por: Bonnet, F., et al.
Publicado: (2020)

Incidence and Risk Factors for Severe Bacterial Infections in People Living with HIV. ANRS CO3 Aquitaine Cohort, 2000–2012
por: Collin, Amandine, et al.
Publicado: (2016)

Role of Traditional Risk Factors and Antiretroviral Drugs in the Incidence of Chronic Kidney Disease, ANRS CO3 Aquitaine Cohort, France, 2004–2012
por: Morlat, Philippe, et al.
Publicado: (2013)

Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014
por: Cazanave, Charles, et al.
Publicado: (2015)

Bacterial Pneumonia among HIV-Infected Patients: Decreased Risk After Tobacco Smoking Cessation. ANRS CO3 Aquitaine Cohort, 2000–2007
por: Bénard, Antoine, et al.
Publicado: (2010)

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010)

Severe Morbidity According to Sex in the Era of Combined Antiretroviral Therapy: The ANRS CO3 Aquitaine Cohort
por: Hessamfar, Mojgan, et al.
Publicado: (2014)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study
por: Mandelbrot, Laurent, et al.
Publicado: (2023)

Factors associated with poorer quality of life in people living with HIV in southwestern France in 2018–2020 (ANRS CO3 AQUIVIH-NA cohort: QuAliV study)
por: Barger, Diana, et al.
Publicado: (2023)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Tobacco, alcohol, cannabis, and illicit drug use and their association with CD4/CD8 cell count ratio in people with controlled HIV: a cross-sectional study (ANRS CO3 AQUIVIH-NA-QuAliV)
por: Devos, Sophie, et al.
Publicado: (2023)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

One year of SARS-CoV-2 circulation in the Nouvelle-Aquitaine region, February 2021–2022, France
por: Deroche, Luc, et al.
Publicado: (2023)

Combating HIV resistance – focus on darunavir
por: Tremblay, Cécile L
Publicado: (2008)

Role of darunavir in the management of HIV infection
por: Lascar, R Monica, et al.
Publicado: (2009)

Darunavir pharmacokinetics throughout pregnancy and postpartum
por: Lambert, John, et al.
Publicado: (2014)

Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014)

Immunodeficiency, HIV RNA plasma viral load and risk of AIDS-defining and non-AIDS-defining neoplasia, ANRS CO3 Aquitaine Cohort (1998–2006)
por: Bruyand, M, et al.
Publicado: (2009)

Appropriate clinical use of darunavir 800 mg
por: Moorhouse, Michelle A., et al.
Publicado: (2018)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2015)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

2482. Clinical Outcomes of Once-Daily Darunavir in Treatment-Experienced Patients with Darunavir Resistance Associated Mutations Through 48 Weeks of Treatment
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2019)

Integrating Electronic Patient-Reported Outcome Measures into Routine HIV Care and the ANRS CO3 Aquitaine Cohort’s Data Capture and Visualization System (QuAliV): Protocol for a Formative Research Study
por: Barger, Diana, et al.
Publicado: (2018)

Profile of darunavir in the management of treatment-experienced HIV patients
por: Wolfe, Cameron, et al.
Publicado: (2009)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Temporal trend of the first prescription of nevirapine: the ANRS CO3 Aquitaine Cohort, 1997-2008
por: Bruyand, M, et al.
Publicado: (2010)

Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)
por: Charpentier, Charlotte, et al.
Publicado: (2013)

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial
por: Ammassari, Adriana, et al.
Publicado: (2018)

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2020)

Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 Weeks
por: Lambert-Niclot, Sidonie, et al.
Publicado: (2012)

Molecular designing and in silico evaluation of darunavir derivatives as anticancer agents
por: Mahto, Manoj kumar, et al.
Publicado: (2014)

Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
por: Dobroszycki, Joanna, et al.
Publicado: (2011)

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy
por: Colbers, Angela, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vf690b1pquui60pso94fvmioo2